Stroke: success for extending acute treatment

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 2-4

  Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BRAIN HEMORRHAGE; CHRONOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE; THERAPY DELAY; TREATMENT OUTCOME;

EID: 57149090273     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70270-9     Document Type: Note

References (9)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
2. Hacke W., Donnan G., Fieschi C., et al., ATLANTIS, ECASS and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
3. Wahlgren N., Ahmed N., Dávalos A., et al., SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-328
4. Wahlgren N., Ahmed N., Dávalos A., et al., SITS investigators. Thrombolysis with alteplase 3 to 4.5 h after acute ischaemic stroke in the Safe Implementation of Treatments in Stroke Register (SITS-ISTR): an observational study. Lancet 372 (2008) 1303-1309
5. Hacke W., Kaste M., Bluhmki E., et al., European Cooperative Acute Stroke Study (ECASS) investigators. Alteplase compared with placebo within 3 to 4.h hours for acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
6. Davis S.M., Donnan G.A., Parsons M.W., et al., EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7 (2008) 299-309
7. Mayer S.A., Brun N.C., Begtrup K., et al., FAST Trial Investigators. Efficacy and safety of recombinant activated Factor VII for acute intracerebral hemorrhage. N Engl J Med 358 (2008) 2127-2137
8. Mayer S.A., Brun N.C., Begtrup K., et al., Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated Factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
9. Anderson C.S., Huang Y., Wang J.G., and INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 7 (2008) 391-399